JP2017519501A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519501A5
JP2017519501A5 JP2016573833A JP2016573833A JP2017519501A5 JP 2017519501 A5 JP2017519501 A5 JP 2017519501A5 JP 2016573833 A JP2016573833 A JP 2016573833A JP 2016573833 A JP2016573833 A JP 2016573833A JP 2017519501 A5 JP2017519501 A5 JP 2017519501A5
Authority
JP
Japan
Prior art keywords
antibody
axl
domain
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016573833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519501A (ja
JP6787795B2 (ja
Filing date
Publication date
Priority claimed from GBGB1410826.0A external-priority patent/GB201410826D0/en
Application filed filed Critical
Publication of JP2017519501A publication Critical patent/JP2017519501A/ja
Publication of JP2017519501A5 publication Critical patent/JP2017519501A5/ja
Application granted granted Critical
Publication of JP6787795B2 publication Critical patent/JP6787795B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016573833A 2014-06-18 2015-06-18 抗Ａｘｌ抗体 Active JP6787795B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1410826.0 2014-06-18
GBGB1410826.0A GB201410826D0 (en) 2014-06-18 2014-06-18 Anti-axl antibodies
PCT/EP2015/063700 WO2015193428A1 (en) 2014-06-18 2015-06-18 Anti-axl antibodies

Publications (3)

Publication Number Publication Date
JP2017519501A JP2017519501A (ja) 2017-07-20
JP2017519501A5 true JP2017519501A5 (2) 2018-05-10
JP6787795B2 JP6787795B2 (ja) 2020-11-18

Family

ID=51266761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016573833A Active JP6787795B2 (ja) 2014-06-18 2015-06-18 抗Ａｘｌ抗体

Country Status (15)

Country Link
US (3) US9975954B2 (2)
EP (1) EP3157559B1 (2)
JP (1) JP6787795B2 (2)
KR (1) KR102453226B1 (2)
CN (2) CN106573979B (2)
AU (1) AU2015276153B2 (2)
CA (1) CA2952296A1 (2)
DK (1) DK3157559T3 (2)
GB (1) GB201410826D0 (2)
HR (1) HRP20201091T1 (2)
HU (1) HUE049755T2 (2)
LT (1) LT3157559T (2)
MX (1) MX388222B (2)
SI (1) SI3157559T1 (2)
WO (1) WO2015193428A1 (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
JP6864953B2 (ja) * 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
JP6931609B2 (ja) * 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
MX375569B (es) * 2017-02-08 2025-03-04 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
JP2021523379A (ja) * 2018-05-14 2021-09-02 ベルゲンビオ アーエスアー 血清バイオマーカー
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
EP3946453A4 (en) * 2019-03-29 2022-12-07 Celldex Therapeutics, Inc. ANTI-AXL ANTIBODIES AND THEIR METHODS OF USE
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN113045664B (zh) * 2019-11-28 2023-05-12 尚健单抗（北京）生物技术有限公司 一种分离的结合抗原axl的蛋白及其用途
WO2021154156A1 (en) * 2020-01-31 2021-08-05 Agency For Science, Technology And Research Anti-axl antibody and uses thereof
AR121441A1 (es) * 2020-02-28 2022-06-08 Symphogen As Anticuerpos anti-axl y composiciones
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
WO2021204713A1 (en) 2020-04-08 2021-10-14 Bergenbio Asa Axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
IL289525B2 (en) * 2021-12-30 2023-03-01 B G Negev Technologies And Applications Ltd At Ben Gurion Univ Conjugated antibodies for cancer treatment
CN116348497B (zh) * 2023-01-05 2023-11-17 浙江时迈药业有限公司 针对axl的抗体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
AU2008323206B2 (en) * 2007-11-12 2014-08-14 U3 Pharma Gmbh AXL antibodies
CA2706549A1 (en) 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
EP2198884A1 (en) * 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
EP2270053A1 (en) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
KR20120024763A (ko) * 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
BR112012027995A2 (pt) * 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
CN103747803B (zh) * 2011-06-22 2016-10-12 国家医疗保健研究所 抗axl抗体及其用途
AU2012273954A1 (en) * 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
JP6931609B2 (ja) * 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
GB201506411D0 (en) * 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
ES2977788T3 (es) * 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco

Similar Documents

Publication Publication Date Title
JP2017519501A5 (2)
JP2017526339A5 (2)
JP7334177B2 (ja) 抗ｃｄ７３抗体及びその使用
US20210388105A1 (en) Novel anti-cd39 antibodies
JP2018506961A5 (2)
JP2021008487A (ja) 抗ｎｋｇ２ａ抗体を使用した治療計画
JP6529498B2 (ja) ＥＧＦＲｖＩＩＩに対して特異的な抗体結合部位
CN102741282B (zh) 针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途
JP2017535257A5 (2)
WO2020011970A1 (en) Anti-mesothelin antibodies
JP6608698B2 (ja) Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
JP2017522903A5 (2)
JP2017529838A5 (2)
JP2013527761A5 (2)
AU2020212534B2 (en) High affinity monoclonal antibodies targeting glypican-1 and methods of use
JP2021501744A5 (2)
JP2020534830A5 (2)
HRP20180352T1 (hr) Protutijela anti-fcrh5
JP2018500014A5 (2)
JP2017530692A5 (2)
JP2016536342A5 (2)
JP2019534705A5 (2)
JP2012521217A5 (2)
KR20230016186A (ko) 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법
JP2013519364A5 (2)